Showing results (221-230 of 305) with videos related to

Sort By:
Pageof 31
Haematologica|October 5, 2019
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trialSara Bringhen, Mattia D'Agostino, Laura Paris, et al.
Hemasphere|August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma NetworkGrigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
Haematologica|August 10, 2012
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trialsAntonio Palumbo, Anders Waage, Cyrille Hulin, et al.
Haematologica|November 20, 2023
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agentsRoberto Mina, Maria Teresa Petrucci, Francesca Bonello, et al.
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Haematologica|July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. HydePellegrino Musto, Monika Engelhardt, Jo Caers, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Cancer|May 27, 2003
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrenceCorrado Tarella, Alessandra Cuttica, Umberto Vitolo, et al.
Haematologica|October 2, 2025
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncologyAnna J T Smit, Niek G Van der Maas, Bronno Van der Holt, et al.
The Lancet. Oncology|November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trialFrancesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
Pageof 31